Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 15/20 | 0.53 |
| ▸ | DRD2 | P14416 | 15/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18488318 | 0.88 | DRD2 (0.53) | DRD3DRD2KCNH2CHRM1CHRM3 | |
| SCHEMBL18454267 | 0.87 | ALDH1A1 (0.57) | DRD3DRD2KCNH2KDM4EALDH1A1 | |
| SCHEMBL17712959 | 0.86 | ALDH1A1 (0.59) | DRD3DRD2KCNH2KDM4EALDH1A1 | |
| SCHEMBL17725148 | 0.84 | MEN1 (0.59) | DRD3DRD2KCNH2CHRM1CHRM3 | |
| SCHEMBL23465959 | 0.83 | DRD3 (0.62) | DRD3DRD2KCNH2CHRM1CHRM3 | |
| SCHEMBL17713084 | 0.82 | DRD2 (0.50) | DRD3DRD2KCNH2CHRM1CHRM3 | |
| SCHEMBL17712913 | 0.79 | DRD2 (0.54) | DRD3DRD2KCNH2CHRM1CHRM3 | |
| SCHEMBL18452270 | 0.78 | ALDH1A1 (0.42) | DRD3DRD2KCNH2CHRM1CHRM3 | |
| SCHEMBL18453604 | 0.78 | DRD3 (0.51) | DRD3DRD2KCNH2CHRM1CHRM3 | |
| SCHEMBL17712763 | 0.77 | DRD3 (0.52) | DRD3DRD2KCNH2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| EP-3331886-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LTD (GB) | 2020-07-15 | — | — | EP | disclosed |
| EP-3331886-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LTD (GB) | 2020-07-15 | — | — | EP | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| CN-107108597-B | Dopamine D3 receptor antagonist compounds | 英立维尔英国有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-10584135-B2 | Substituted 3,6-diazabicyclo[3.2.0]heptanes | INDIVIOR UK LIMITED (GB) | 2020-03-10 | — | — | US | disclosed |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2019-10-03 | — | — | US | disclosed |
| US-20100152195-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-06-17 | — | — | US | disclosed |
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-2070922-A1 | Azabicyclo(3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2009-06-17 | — | — | EP | disclosed |
| EP-2060570-A2 | Azabicyclo(3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | Glaxo Group Limited (GB) | 2009-05-20 | — | — | EP | disclosed |
| US-20090036461-A1 | Use of Azabicyclo Hexane Derivatives | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
| US-20070142438-A1 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| EP-1745040-A1 | AZABICYCLO(3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005080382-A1 | AZABICYCLO (3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142438-A1 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine d3 receptors | DRD3, DRD1, DRD2 | DRD3 1/4885DRD2 3/4885KCNH2 192/4885 |
| US-20100152195-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | DRD3, DRD1, DRD2 | DRD3 1/4885DRD2 3/4885KCNH2 176/4885 |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | DRD3 1/4885DRD2 2/4885KCNH2 1283/4885 |
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | DRD3, DRD2, SLC6A3 | DRD3 1/4885DRD2 2/4885KCNH2 856/4885 |
| US-20090036461-A1 | Use of Azabicyclo Hexane Derivatives | ADH1C, PKD1, HTT | DRD3 152/4885DRD2 279/4885KCNH2 3743/4885 |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | DRD3 1/4885DRD2 2/4885KCNH2 1283/4885 |
| US-10584135-B2 | Substituted 3,6-diazabicyclo[3.2.0]heptanes | DRD3, DRD2, SLC6A3 | DRD3 1/4885DRD2 2/4885KCNH2 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.